Main > NEUROLOGY. > USA. G. MS (PPMS & RMS)>Treat.>

---

USA. G. MS (PPMS & RMS)>Treat.>'s subsections
(*) EU CE Mark Date: 2020. 05
(*) USA Approval Date: 2020. 12.14
>CD20 MAb 2-Hour Infusion 2/Year
Company
Generic Name: OcrelizuMAb
Patent>Assignee; Claims; No.; Etc
Patent>Total USA No.: 2
Patent>UpDate: 2021. 12.21
RTM
RTM Web-Site

USA. G. MS (PPMS & RMS)>Treat.>'s products
This section has no products